Jan. 26 at 7:58 PM
$PBYI
NERLYNX is being made available in Thailand by independent pharmaceutical company, Specialised Therapeutics (ST), under exclusive license from Puma Biotechnology, Inc. (Nasdaq: PBYI).
A NEW breast cancer therapy shown to significantly reduce the risk of cancer recurrence and improve disease-free survival in women is now available in Thailand.
Delivered as an oral tablet, NERLYNX® (neratinib) was approved for use by the Thai FDA
In early breast cancer, NERLYNX has been shown to significantly reduce the ongoing risk of recurrence in HER2+ women, with the greatest benefit seen in women who are also hormone-receptor positive (HR+) and who commence therapy within 12 months of completing trastuzumab-based therapy.2,3 For these women, the five-year risk of recurrence is reduced by up to 42%.
https://www.prnewswire.com/news-releases/new-breast-cancer-therapy-to-reduce-risk-of-recurrence-and-improve-disease-free-survival-now-available-in-thailand-302666471.html
